Where relevant, the presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at ...

Immunocore Holdings (NASDAQ:IMCR) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Needham has initiated coverage on Immunocore Holdings Plc IMCR with a Buy rating and a price target of $75. Needham analyst Gil Blum says Immunocore has achieved a significant milestone as the pioneer ...

Immunocore Hldgs (NASDAQ:IMCR) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June 2023) Immunocore (IMCR) Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel ...

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were ...

Immunocore (IMCR) announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous ...

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, ...